Mr. Fischer is a co-founder of Goodwin Biotechnology Inc. and currently serves as the Executive Vice President of Client Operations. Prior to co-founding GBI, Mr. Fischer held increasingly responsible positions in manufacturing, materials management, and sales and marketing with Abbott Laboratories, Amersham Corporation, and Immunomedics. Mr. Fischer has over 30 years experience with biological products in both therapeutic and diagnostic applications. He earned a Master of Business Administration from Roosevelt University in Chicago , and a Bachelor of Business Administration from the University of Wisconsin in Madison.

Zafeer Ahmad, Ph.D.
Senior Vice President, Operations

Dr. Ahmad most recently held the position of Vice President, Manufacturing Operations at Bradmer Pharmaceuticals Inc. Prior to joining Bradmer Pharmaceuticals, Dr. Ahmad was Vice President of Process Development and Manufacturing group at NeoPharm. Inc. Dr. Ahmad also held senior positions at GlaxoSmithKline plc and Hoffmann-La Roche Inc. He has more than 21 years of industry experience in drug development, aseptic manufacturing operations, facility design and validation, batch record and SOP preparation, outsourcing, tech transfer, process validation and regulatory submission of drugs. Based on this experience, Dr. Ahmad has a strong working knowledge of cGMP and CMC documentation for IND and BLA preparation. From an academic perspective, Dr. Ahmad held the position of Senior Scientist/Assistant Professor at Indiana University, and was a Visiting Fellow at the National Institutes of Health in Bethesda, MD. He received his Ph.D in Biochemistry from Aligarh University in India. He has published numerous peer reviewed articles including nine papers in the Journal of Biological Chemistry.

Dr. Sesay has over 8 years industrial experience in bioconjugation and modification of biological molecules (including monoclonal and polyclonal antibodies, enzymes, toxins and others) and small molecules and over 15 years of experience in the biotechnology sectors. Prior to GBI, Muctarr supervised many projects in R&D, Process Development and Manufacturing of biologics at Life Technologies (now Invitrogen), Kirkegaard and Perry Lab and Elusys Therapeutics. Muctarr, after receiving his Ph.D in Biochemistry from the University of London, England worked for 3 years postdoctoral candidate at the University of Maryland , College Park in Protein Purification and characterization.

Mr. Zeichner brings over 25 years experience in the business development area with both pharma and biopharm service provider and supplier organizations. He was most recently director of business development at Laureate Pharma where at various times he supervised world-wide sales as well as all marketing programs, along with establishing major cooperative alliances with relevant partner companies. Prior to Laureate he was regional sales manager for Irvine Scientific where he promoted their extensive line of cell culture services and products. Before that, Stan was manager of business development for BioScience Contract Production where his sales and marketing programs helped raise the value of the company to facilitate a sale to Cambrex Corp. for $120M. Stan has a MS in Biochemistry from Fairleigh Dickinson University and a BA in Chemistry from Hunter College.

Dr. Dasarathy has over 17 years of experience in marketing to the life sciences and pharmaceutical Industry. Prior to joining GBI, Yamuna was a Senior Marketing Manager, promoting Laureate Pharma’s biologics manufacturing services. Prior to that she held various strategic positions at GE Healthcare Biosciences covering technical services and downstream process development, and was managing marketing of over a $100 million product portfolio. Yamuna’s academic experience includes an Assistant Professorship at Tufts-New England Medical Center, Boston and a post doctoral fellowship at Brandeis University. She has a PhD in Biochemistry from University of Madras, India and an MBA from Rutgers University, NJ.